RESUMEN
OBJECTIVES: Adopting a unique Spanish perspective, this study aims to assess healthcare resource utilization (HCRU) and the costs of treating nosocomial pneumonia (NP) produced by methicillin-resistant Staphylococcus aureus (MRSA) in hospitalized adults using linezolid or vancomycin. An evaluation is also made of the renal failure rate and related economic outcomes between study groups. DESIGN: An economic post hoc evaluation of a randomized, double-blind, multicenter phase 4 study was carried out. SCOPE: Nosocomial pneumonia due to MRSA in hospitalized adults. PARTICIPANTS: The modified intent to treat (mITT) population comprised 224 linezolid- and 224 vancomycin-treated patients. INTERVENTIONS: Costs and HCRU were evaluated between patients administered either linezolid or vancomycin, and between patients who developed renal failure and those who did not. PRIMARY ENDPOINTS: Analysis of HCRU outcomes and costs. RESULTS: Total costs were similar between the linezolid- (17,782±9,615) and vancomycin-treated patients (17,423±9,460) (P=.69). The renal failure rate was significantly lower in the linezolid-treated patients (4% vs. 15%; P<.001). The total costs tended to be higher in patients who developed renal failure (19,626±10,840 vs. 17,388±9,369; P=.14). Among the patients who developed renal failure, HCRU (days on mechanical ventilation: 13.2±10.7 vs. 7.6±3.6 days; P=.21; ICU stay: 14.4±10.5 vs. 9.9±6.6 days; P=.30; hospital stay: 19.5±9.5 vs. 16.1±11.0 days; P=.26) and cost (17,219±8,792 vs. 20,263±11,350; P=.51) tended to be lower in the linezolid- vs. vancomycin-treated patients. There were no statistically significant differences in costs per patient-day between cohorts after correcting for mortality (1000 vs. 1,010; P=.98). CONCLUSIONS: From a Spanish perspective, there were no statistically significant differences in total costs between the linezolid and vancomycin pneumonia cohorts. The drug cost corresponding to linezolid was partially offset by fewer renal failure adverse events.
Asunto(s)
Antibacterianos/economía , Antibacterianos/uso terapéutico , Infección Hospitalaria , Costos de la Atención en Salud , Staphylococcus aureus Resistente a Meticilina , Neumonía Estafilocócica/economía , Método Doble Ciego , Humanos , Linezolid/economía , Linezolid/uso terapéutico , Meticilina , Neumonía Estafilocócica/tratamiento farmacológico , Ensayos Clínicos Controlados Aleatorios como Asunto , Resultado del Tratamiento , Vancomicina/economía , Vancomicina/uso terapéuticoRESUMEN
The objective of this study was to document pan-European real-world treatment patterns and healthcare resource use and estimate opportunities for early switch (ES) from intravenous (IV) to oral antibiotics and early discharge (ED) in hospitalized patients with methicillin-resistant Staphylococcus aureus (MRSA) complicated skin and soft tissue infections (cSSTIs). This retrospective observational medical chart review study enrolled 342 physicians across 12 European countries who collected data from 1542 patients with documented MRSA cSSTI who were hospitalized (July 2010 to June 2011) and discharged alive (by July 2011). Data included clinical characteristics and outcomes, hospital length of stay (LOS), MRSA-targeted IV and oral antibiotic use, and ES and ED eligibility according to literature-based and expert-validated criteria. The most frequent initial MRSA-active antibiotics were vancomycin (50.2%), linezolid (15.1%), clindamycin (10.8%), and teicoplanin (10.4%). Patients discharged with MRSA-active antibiotics (n = 480) were most frequently prescribed linezolid (42.1%) and clindamycin (19.8%). IV treatment duration (9.3 ± 6.5 vs. 14.6 ± 9.9 days; p <0.001) and hospital LOS (19.1 ± 12.9 vs. 21.0 ± 18.2 days; p 0.162) tended to be shorter for patients switched from IV to oral treatment than for patients who received IV treatment only. Of the patients, 33.6% met ES criteria and could have discontinued IV treatment 6.0 ± 5.5 days earlier, and 37.9% met ED criteria and could have been discharged 6.2 ± 8.2 days earlier. More than one-third of European patients hospitalized for MRSA cSSTI could be eligible for ES and ED, resulting in substantial reductions in IV days and bed-days, with potential savings of 2000 per ED-eligible patient.
Asunto(s)
Antibacterianos/administración & dosificación , Tiempo de Internación/tendencias , Staphylococcus aureus Resistente a Meticilina/efectos de los fármacos , Enfermedades Cutáneas Bacterianas/tratamiento farmacológico , Infecciones de los Tejidos Blandos/tratamiento farmacológico , Infecciones Estafilocócicas/tratamiento farmacológico , Administración Intravenosa , Administración Oral , Anciano , Femenino , Humanos , Tiempo de Internación/economía , Masculino , Persona de Mediana Edad , Alta del Paciente , Estudios Retrospectivos , Enfermedades Cutáneas Bacterianas/microbiología , Infecciones de los Tejidos Blandos/microbiología , Infecciones Estafilocócicas/complicacionesRESUMEN
A major priority for funding agencies and researchers involved in comparative-effectiveness research (CER) is to ensure that research questions will produce findings that are relevant and feasible to implement. In this article, we describe a process for involving experts and stakeholders in identifying and prioritizing CER studies, as illustrated by our experience in chronic obstructive pulmonary disease (COPD).
Asunto(s)
Investigación sobre la Eficacia Comparativa/métodos , Enfermedad Pulmonar Obstructiva Crónica/tratamiento farmacológico , Apoyo a la Investigación como Asunto , Toma de Decisiones , Humanos , Formulación de Políticas , Estados UnidosRESUMEN
Few data exist on the impact of age and inhibitor status on activity levels among patients with severe and moderately severe haemophilia A. The aim of this analysis was to assess the impact of age, race/ethnicity and inhibitor status on functional limitations through retrospective analysis of data from the Hemophilia and Thrombosis Research Society (HTRS) Registry. Functional status data from patients with haemophilia A with or without inhibitors who were enrolled in the HTRS Registry between October 1999 and July 2008 were analysed by age, race and ethnicity. Of the 2497 registrants, 1340 had congenital haemophilia A (333 with inhibitors). Functional status was available for 274 subjects with haemophilia A with current inhibitors and 247 subjects without inhibitors who had moderately severe (FVIII levels ≤ 2%). Functional impairment increased with age across five levels of functional status (P < 0.01). Inhibitors were associated with greater functional impairment in two age groups (13-21 years and older than 21 years) [unrestricted activity in 57.8% vs. 63.6% (P = 0.06) and 18.3% vs. 28.6% (P = 0.04), respectively]. Blacks had worse functional status than caucasians across all ages regardless of inhibitor status. Functional status decreases with age, and impairment is greater among patients with inhibitors beginning in adolescence. These results reaffirm the need for early eradication of inhibitors and early treatment of bleeds in inhibitor and non-inhibitor patients. This analysis highlights the benefit of ongoing study of these patients through data collected for the HTRS Registry.